View all newsletters
Receive our newsletter – data, insights and analysis delivered to you

Adare Pharmaceuticals

Oral Drug Delivery Technologies and Drug Development

Adare Pharmaceuticals transforms medicines, creating new possibilities for improved patient health.

Princeton Pike Corporate Center
1200 Lenox Drive, Suite 100,
New Jersey,
United States of America
Fax Number
Taste masking and customised drug development

Adare Pharmaceuticals transforms medicines, creating new possibilities for improved patient health.

For decades, the company has successfully overcome complex formulation challenges in specialized and diverse therapeutic categories such as cardiovascular, pain management, gastrointestinal (GI) and central nervous system (CNS), delivering medicines that benefit patients.

Using proprietary technologies, including taste masking and orally disintegrating tablets (ODT), customized drug release, and bioavailability enhancement, Adare has demonstrated the unique ability to transform drug formulations and create novel Rx and over-the-counter (OTC) products.

In addition, Adare can add valuable IP to commercialized products and products in development for business partners worldwide. With global research and development (R&D) and manufacturing facilities, Adare brings complex products from development to commercialization.

Adare Pharmaceuticals develops, manufactures, and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies.
We develop novel, value-added products that can bring benefits to patients.
Our facilities in the US and in Europe supply products to many regions of the world.
More than 40 products, spanning a range of therapeutic categories, have been developed by Adare Pharmaceuticals and are commercialized by our partners worldwide.
The Multi Mini Tablet System controlled release technology offers flexible dose delivery, which may improve adherence.
AdvaTab® and Microcaps® are taste-masking technologies to help adherence by masking undesirable flavours with more pleasant tastes.

Since 2009, Adare’s partnerships have resulted in more than 60 product launches in 44 countries.

Taste masking technology platform

Adare offers proprietary technologies that provide taste masked products with a pleasant taste and excellent mouth-feel for patient appeal. These technologies include AdvaTab®, Liquitard®, and Microcaps®.

Customized drug release technology platform

The customized drug release technology platform consists of various technologies that provide a range of customized release profiles. These drug release profiles can be tailored to optimize a drug’s therapeutic performance by improving efficacy and enhancing safety.

Patient acceptability and compliance can be increased through less frequent dosing. Adare’s proprietary customized drug release technologies include Diffucaps®, Eurand Minitabs®, and Diffutab®.

Bioavailability enhancement technology platform

Adare provides technologies to enable and improve the bioavailability of drugs with low solubility or an extreme pH-dependent solubility profile.

The resulting formulations can offer effective oral dosing of poorly soluble drug candidates, equivalent therapy at lower doses, faster onset of action, and minimization of food effect. The bioavailability enhancement technologies provided by Adare include Biorise™ and Diffucaps® (solid solution or solid dispersion).

Collaborations and clients

The company meets its partners’ business needs by offering technologies and resources for the development of new product formulations or licensing availability of existing product formulations (both Rx and OTC.)

Adare’s partnership process provides its clients with an experienced management team across all functions and stages of the product development cycle.

Adare has a multinational infrastructure and integrated R&D and manufacturing facilities in the US and Europe, thereby delivering global solutions to companies in various regions worldwide.

The company’s global business development and licensing teams aim to provide flexible deal structures to help maximize its partners’ interests.

Forest Laboratories to Acquire Aptalis

Aptalis has signed a definitive agreement to be acquired by Forest Laboratories, a leading, fully integrated, specialty pharmaceutical company, for $2.9bn in cash pending required reviews.

15 January 2014

Aptalis Pharmaceutical Technologies Expands Licensing Team

Aptalis Pharmaceutical Technologies, a business unit of Aptalis Pharma that develops differentiated products utilizing its oral delivery technologies, today announces that Nigel Ray has been named as the company's Vice President of Global Licensing.

14 February 2013

Aptalis Announces European Commission Approval for New Formulation of Viread®

Aptalis Pharmaceutical Technologies, formerly Eurand Pharmaceutical Technologies, focused on developing differentiated oral products utilising its pharmaceutical technologies, today announced that the European Commission has granted marketing authorisation for a new pediatric indication of a new oral granule formulation of Gilead Sciences's Viread® (tenofovir disoproxil fumarate) for HIV-1 infected children aged two to six years of age, and for HIV-1 infected children above six years of age for whom a solid dosage form is not appropriate.

13 December 2012

PharmaTelevision Interview to Spotlight Aptalis Pharma’s Year in Review

FDA approvals, revenue gain and organic business growth are just a few of the topics that Aptalis Pharma president John Fraher addresses during an on-air interview with PharmaVentures and PharmaTelevision CEO Fintan Walton. The interview, conducted during BIO 2012 in Boston, reflects Fraher's commentary regarding the integration of companies post Axcan Intermediate Holdings' acquisition of Eurand NV in 2011.

6 September 2012

Aptalis Wins Appeal Against Generic Version of AMRIX

Aptalis (previously known as Eurand, Inc.), Cephalon, a wholly-owned subsidiary of Teva Pharmaceuticals Industries Ltd, and Anesta AG prevailed in their appeal to the U.S. Court of Appeals for the Federal Circuit, which reversed a lower court's determination and held that two patents covering the AMRIX muscle relaxant (Cyclobenzaprine Hydrochloride Extended-Release Capsules) are valid.

24 April 2012

PharmaTelevision Interview to Spotlight Aptalis Pharma President John Fraher

Company strategy, portfolio development and emerging markets are just a few of the topics that John Fraher, president of Aptalis Pharma, is scheduled to address during an on-air interview with Fintan Walton, CEO, PharmaVentures and PharmaTelevision. The interview is available via on-demand at Pha

22 August 2011

Eurand to Discuss Strategic Decision-Making at BioEurope Spring

Steve Ellul, Eurand's director of licensing, will discuss aspects of the company's growth strategy during the session 'Understanding the Drivers for Strategic Decision-Making' at BioEurope Spring in Milan, Italy, on Monday 14 March from 9am to 10.30am local time. The panel of industry

10 March 2011

Eurand Enters Agreement With Nycomed for ZENPEP in Russia-CIS

Eurand, a global specialty pharmaceutical company, and Nycomed, a privately owned global pharmaceutical company, have announced an exclusive commercialization, license and supply agreement for Russia and the Commonwealth of Independent States (CIS), as well as Georgia and Mongolia. Financial term

12 January 2011

Eurand Presents Taste-Masking Technology Webinar

Eurand, a global specialty pharmaceutical company, has conducted a webinar titled 'The $10 Billion Gap: Leveraging Taste-Masking Technologies to Meet Global Patient Needs', presented by Troy Harmon, vice president of business development, and Andrew Thompson, vice president of commercial operatio

9 November 2010

Eurand Reports Recent Highlights and Second Quarter 2010 Financial Results

Eurand, a global specialty pharmaceutical company, today reported revenues for the second quarter of 2010 of €32.9m ($40.5m), an increase of 8%, or 3% in constant currency, from the second quarter of 2009. For the six months ended 30 June 2010, revenues totaled €64m ($78.7m), up

5 August 2010

Eurand Issued US Patent for ZENPEP (pancrelipase) Delayed-Release Capsules

Eurand, a global specialty pharmaceutical company, announced today the grant of US Patent No. 7,658,918, titled 'Stable digestive enzyme compositions', by the United States Patent and Trademark Office (USPTO). The patent will provide Eurand with coverage until at least 20 February 2028 on ZENPEP&

15 February 2010

Adare Pharmaceuticals

Princeton Pike Corporate Center
1200 Lenox Drive, Suite 100
New Jersey
United States of America

Adare Pharmaceuticals

Via Martin Luther King, 13
20060, Pessano con Bornago

Adare Pharmaceuticals

845 Center Drive
United States of America

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology